On January 3, Jiangsu Hengrui Medicine Co.Ltd(600276) announced that recently, the State Drug Administration approved the listing of Jiangsu Hengrui Medicine Co.Ltd(600276) two innovative drugs. So far, Jiangsu Hengrui Medicine Co.Ltd(600276) has reached 10 innovative drugs on the market.
Jiangsu Hengrui Medicine Co.Ltd(600276) the two innovative drugs approved this time are darcilil hydroxyethanesulfonate tablets and proline hengglijing tablets, both of which are class 1 new drugs.
Dulcie Lee is China’s first CDK4/6 inhibitor, and this approved indication is the treatment of recurrent or metastatic breast cancer with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative after endocrine therapy. The listing application was included in the priority review and approval procedure by the State Food and drug administration according to breakthrough treatment varieties in April 2021. As a new highly selective CDK4/6 inhibitor, Dahl Sealy has made innovations in the molecular structure of drugs. Its listing will strongly promote the accessibility of CDK4/6 inhibitors, and will bring new therapeutic options for more HR+/HER2- breast cancer patients.
Heng Ge Ling Jing is the first domestic innovative SGLT2 inhibitor approved for improving glycemic control in adults with type 2 diabetes. In recent years, Jiangsu Hengrui Medicine Co.Ltd(600276) has made extensive research and development of pipeline layout in the field of diabetes, and Jiangsu Hengrui Medicine Co.Ltd(600276) is the first innovative drug in the field. At present, hengglijing is still developing compound preparations with metformin and DPP4 inhibitors, which will provide more diversified choices for clinical application.
(China Securities Journal · China Securities Network)
